BridgeMD
New treatment option for Primary Central Nervous System Lymphoma
Official title Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
ClinicalTrials.gov ID: NCT06832267
What this study is testing
What is Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT)?
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for primary central nervous system lymphoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to observe and explore the efficacy and safety of Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) regimen as first-line therapy for primary central nervous system diffuse large B-cell lymphomas(PCNS DLBCL)
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Patients voluntarily joined the study, signed the informed consent, and had good compliance;
- Patients with 18 Years to 75 Years(at the time of signing the informed consent); Eastern Cooperative Oncology Group Performance Status (ECOG-PS)...
- Patients with histopathologically confirmed newly diagnosed primary central nervous system diffuse large B-cell lymphoma, and there were intracranial...
- Patients who have not received any systemic therapy, except those who use hormones to control complications
- Expected survival of more than 3 months.
You likely can't join if
- Patients who have previously received antitumor therapy or targeted therapy
- Patients who have undergone major surgery within the past 3 weeks .
- Presence of severe or uncontrolled comorbid conditions including, but not limited to, symptomatic congestive heart failure, uncontrolled...
- Any active infection requiring systemic antimicrobial therapy within 14 days before starting study treatment, including, but not limited to...
- Patients who are pregnant or breastfeeding.
- Current participation in other clinical studies, or initiation of study drugs administration less than 4 weeks after completion of previous clinical...
See the full eligibility criteria
- Patients voluntarily joined the study, signed the informed consent, and had good compliance;
- Patients with 18 Years to 75 Years(at the time of signing the informed consent); Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score: 0-3;
- Patients with histopathologically confirmed newly diagnosed primary central nervous system diffuse large B-cell lymphoma, and there were intracranial evaluable lesions (long diameter greater than 1.5cm, short diameter...
- Patients who have not received any systemic therapy, except those who use hormones to control complications
- Expected survival of more than 3 months.
- Female patients of reproductive age should agree that birth control (such as intrauterine device, birth control pills, or condoms) must be used during the study period and for six months after completion; Having a...
- Patients who have previously received antitumor therapy or targeted therapy
- Patients who have undergone major surgery within the past 3 weeks .
- Presence of severe or uncontrolled comorbid conditions including, but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina, active peptic ulcer disease, or severe hemorrhagic...
- Any active infection requiring systemic antimicrobial therapy within 14 days before starting study treatment, including, but not limited to, bacterial, fungal, and viral infections.
- Patients who are pregnant or breastfeeding.
- Current participation in other clinical studies, or initiation of study drugs administration less than 4 weeks after completion of previous clinical study treatment.
- Patients with concomitant diseases that, in the investigator's judgment, may seriously endanger patients' safety or may interfere with the completion of the study, or are deemed unsuitable for inclusion for other...
The study team makes the final eligibility decision.
Where it's taking place
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hangzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.